Font Size: a A A
Keyword [Imatinib]
Result: 181 - 200 | Page: 10 of 10
181. The Clinical And Molecular Research On Therapeutic Effect Of TKIs In Chronic Myeloid Leukemia
182. The Influence Of TET2 On The Growth Of CML Cells
183. Application Effect Of Tyrosine Kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia
184. The Role Of ZFX In Chronic Myeloid Leukemia Stem/progenitor Cells
185. An Analysis On Clinical Of Extragastrointestinal Stromal Tumors
186. Hypereosinophilic Syndrome:a Case Report And Literature Review
187. PDGF/PDGFR May Be Involved In The Physiopathologic Mechanism Of Essential Thrombocythemia
188. Analysis Of Diagnosis And Treatment And Prognosis In 173 Cases Of Patients With Gastrointestinal Stromal Tumor
189. In Vitro And In Vivo Study Of Nickel Pyrithione Overcome Imatinib Resistance In Chronic Myeloid Leukemia
190. The Change Of ErbB Signaling Pathways In Secondary Imatinib Resistant Gastrointestinal Stromal Tumors
191. Synthesis Of Small Molecule Kinase Inhibitors Containing Four-membered Heterocycles And Iridium Catalyzed Reaction
192. Part I: CD4~+CD25~+Foxp3~+ Regulatory T Cell-mediated Immune Escape Mechanism Of Acute Myeloid Leukemia Part II: Analysis Of The Efficacy Of Imatinib In Ph-positive Acute Lymphoblastic Leukemia
193. Preliminary Study On Tumor Targeting Therapy Strategy And Regulation Mechanism Based On The Interaction Between UPS And (inhibition) Oncogene
194. The Effect Of Imatinib Mesylate On Complicance Of Neurogenic Bladder Caused By Spinal Cord Injury On Rats
195. Clinical Observation Of Nilotinib In Patients With Imatinib-resistant Or Intolerant Chronic Myeloid Leukemia
196. Clinical Observation And Analysis Of Generic Imatinib Mesylate Capsules Produced In China For Newly Diagnosed CML Patients
197. Anti-Metastatic Activity Of Imatinib By Suppressing Tumor-Associated Macropahge M2-Like Polarization
198. Mechanism Of SCIN-promoting Invasion In Gastric Cancer Cells And Establishment And Characterization Of A New Gastric GIST Cell Line
199. Progress In Eosinophilic Disorders
200. Analysis Of Clinical Efficacy Of The Second Generation Tyrosine Kinase Inhibitor For CML-CP Patients Without Optimal Response To Imatinib
  <<First  <Prev  Next>  Last>>  Jump to